Janux Therapeutics Q2 EPS $(0.42) Beats $(0.52) Estimate, Sales $1.06M Beat $870.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Janux Therapeutics reported Q2 earnings per share (EPS) of $(0.42), beating the analyst consensus estimate of $(0.52) by 19.23%. However, this is a 2.44% decrease from the same period last year. The company also reported quarterly sales of $1.06M, surpassing the analyst consensus estimate of $870.00K by 21.49%, but this is a 55.31% decrease from the same period last year.
August 08, 2023 | 9:07 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Janux Therapeutics reported better-than-expected Q2 earnings and sales, but both figures decreased compared to the same period last year.
While Janux Therapeutics beat analyst estimates for Q2, the decrease in both earnings per share and sales compared to the same period last year could potentially offset any positive impact from the earnings beat. The market's reaction will likely depend on whether investors focus more on the earnings beat or the year-over-year decrease.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100